Janus Henderson Group PLC Acquires Shares of 236,116 Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Janus Henderson Group PLC purchased a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 236,116 shares of the company's stock, valued at approximately $5,840,000. Janus Henderson Group PLC owned about 19.51% of Oruka Therapeutics at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. The Manufacturers Life Insurance Company acquired a new position in shares of Oruka Therapeutics in the 3rd quarter valued at about $1,037,000. Great Point Partners LLC acquired a new position in shares of Oruka Therapeutics in the 3rd quarter valued at about $12,614,000. Braidwell LP acquired a new position in shares of Oruka Therapeutics in the 3rd quarter valued at about $12,640,000. Finally, FMR LLC acquired a new position in shares of Oruka Therapeutics in the 3rd quarter valued at about $114,763,000. Institutional investors own 56.44% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on ORKA shares. Stifel Nicolaus started coverage on Oruka Therapeutics in a research note on Friday, October 11th. They set a "buy" rating and a $49.00 price target on the stock. Leerink Partners started coverage on Oruka Therapeutics in a research note on Tuesday, September 17th. They set an "outperform" rating and a $44.00 price target on the stock. Wedbush reaffirmed an "outperform" rating and set a $40.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Leerink Partnrs raised Oruka Therapeutics to a "strong-buy" rating in a research note on Tuesday, September 17th. Finally, Jefferies Financial Group started coverage on Oruka Therapeutics in a research note on Friday, September 13th. They set a "buy" rating and a $40.00 price target on the stock. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Oruka Therapeutics has an average rating of "Buy" and a consensus target price of $43.17.

Oruka Therapeutics Trading Up 3.7 %

Shares of ORKA stock traded up $0.84 during trading on Tuesday, hitting $23.85. The company's stock had a trading volume of 278,539 shares, compared to its average volume of 70,733. The company has a market cap of $834.75 million, a P/E ratio of -3.81 and a beta of 0.78. The business's fifty day moving average is $25.26. Oruka Therapeutics, Inc. has a 52 week low of $18.20 and a 52 week high of $53.88.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products.